Wai Yuen Tong Medicine Holdings Limited (HK:0897)
:0897
Top Page
Wai Yuen Tong Medicine Holdings Limited
(0897)
Select Model
Select Model
Rating:46Neutral
Price Target:
HK$0.36
▲(0.83% Upside)
Action:ReiteratedDate:11/21/25
The overall stock score reflects a combination of mixed financial performance and technical indicators, along with a high valuation. The company's stable gross profit margins and manageable leverage are offset by challenges in profitability and cash flow management. Technical analysis suggests a neutral to bearish outlook, and the high P/E ratio indicates potential overvaluation, despite an attractive dividend yield.
Positive Factors
Stable gross profit margins
Stable gross margins signal sustainable unit economics in product sourcing and pricing. For a retail and distribution-focused Chinese medicine group, persistent gross margin stability supports long-term gross profit generation even if operating costs fluctuate, enabling feasible margins to fund operations and strategic initiatives.
Negative Factors
Weak cash generation
Negative free cash flow growth and poor conversion of income into cash indicate persistent cash-generation issues. Over time this constrains capital for inventory, store investment, debt servicing, or dividends, forcing reliance on external funding or asset sales to support ongoing operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Stable gross profit margins
Stable gross margins signal sustainable unit economics in product sourcing and pricing. For a retail and distribution-focused Chinese medicine group, persistent gross margin stability supports long-term gross profit generation even if operating costs fluctuate, enabling feasible margins to fund operations and strategic initiatives.
Read all positive factors
Wai Yuen Tong Medicine Holdings Limited (0897) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$416.29M
Dividend Yield7.5%
Average Volume (3M)632.59K
Price to Earnings (P/E)43.6
Beta (1Y)0.13
Revenue Growth59.60%
EPS Growth-351.02%
CountryHK
Employees817
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)<0.01
Shares Outstanding1,125,102,900
10 Day Avg. Volume746,291
30 Day Avg. Volume632,591
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)0.34
Price to Sales (P/S)0.54
P/FCF Ratio5.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Wai Yuen Tong Medicine Holdings Limited Business Overview & Revenue Model
Company Description
Wai Yuen Tong Medicine Holdings Limited, an investment holding company, manufactures, processes, and retails traditional Chinese medicines, Western pharmaceutical products, and health food and personal products in Hong Kong, Mainland China, Macau,...
How the Company Makes Money
Wai Yuen Tong makes money primarily by selling products and services tied to Chinese medicine and healthcare through (1) retail and (2) distribution/trading channels. (1) Retail sales: The group generates revenue from sales to consumers in its sel...
Wai Yuen Tong Medicine Holdings Limited Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
55
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 721.27M | 745.30M | 783.88M | 1.29B | 1.39B | 1.11B |
| Gross Profit | 359.73M | 376.45M | 394.81M | 609.54M | 574.15M | 448.26M |
| EBITDA | 90.23M | 122.72M | 116.33M | 115.88M | 156.19M | -102.78M |
| Net Income | -13.83M | 7.10M | -15.36M | -20.52M | -108.91M | -376.00M |
Balance Sheet | ||||||
| Total Assets | 1.69B | 1.74B | 2.10B | 7.01B | 7.60B | 7.96B |
| Cash, Cash Equivalents and Short-Term Investments | 135.68M | 146.55M | 196.78M | 625.01M | 683.74M | 688.93M |
| Total Debt | 301.48M | 435.41M | 560.07M | 1.76B | 1.80B | 1.77B |
| Total Liabilities | 508.14M | 555.68M | 709.65M | 3.33B | 3.64B | 4.01B |
| Stockholders Equity | 1.18B | 1.18B | 1.39B | 2.35B | 2.52B | 2.57B |
Cash Flow | ||||||
| Free Cash Flow | 107.95M | 75.16M | 157.04M | 58.13M | 90.14M | 298.99M |
| Operating Cash Flow | 129.03M | 102.32M | 191.69M | 91.58M | 116.18M | 358.49M |
| Investing Cash Flow | -1.78M | 280.89M | -84.62M | 15.06M | -15.91M | -81.78M |
| Financing Cash Flow | -107.01M | -405.69M | -469.97M | -67.25M | -115.27M | -266.48M |
Wai Yuen Tong Medicine Holdings Limited Technical Analysis
Positive
0.36
Price Trends
0.35
Positive
0.38
Negative
0.37
Negative
Market Momentum
<0.01
Negative
56.65
Neutral
27.94
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0897, the sentiment is Positive. The current price of 0.36 is above the 20-day moving average (MA) of 0.34, above the 50-day MA of 0.35, and below the 200-day MA of 0.37, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 56.65 is Neutral, neither overbought nor oversold. The STOCH value of 27.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0897.
Wai Yuen Tong Medicine Holdings Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$677.60M | 24.59 | 1.57% | 9.43% | -1.99% | -81.52% | |
67 Neutral | HK$747.94M | 4.94 | 9.88% | 7.52% | -24.96% | -26.43% | |
54 Neutral | HK$211.65M | -0.15 | -30.35% | ― | -11.89% | -290.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | HK$416.29M | 43.63 | -1.17% | 7.50% | 59.60% | -351.02% | |
44 Neutral | HK$208.55M | -3.96 | -11.18% | ― | -19.28% | -42.27% | |
42 Neutral | HK$163.16M | -4.22 | -30.35% | ― | -17.32% | 55.74% |
* Healthcare Sector Average
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.37
0.01
2.78%
HK:0858
Extrawell Pharmaceutical Holdings Limited
0.08
0.04
97.62%
HK:0455
Tianda Pharmaceuticals Ltd.
0.10
-0.07
-42.26%
HK:1498
PuraPharm Corp. Ltd.
0.31
-0.20
-39.00%
HK:0239
Pak Fah Yeow International Limited
2.40
0.42
21.21%
HK:3737
Zhongzhi Pharmaceutical Holdings Limited
0.80
0.00
0.00%
Wai Yuen Tong Medicine Holdings Limited Corporate Events
Wai Yuen Tong Tightens Nomination Committee Mandate to Bolster Governance and Board Diversity
Mar 16, 2026
Wai Yuen Tong Medicine Holdings has amended and restated the terms of reference for its nomination committee, effective 16 March 2026, to align with Hong Kong Listing Rules, the Corporate Governance Code and applicable laws. The committee must com...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.